Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Lifted by Forsta AP Fonden

Forsta AP Fonden raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 66.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,420 shares of the biopharmaceutical company’s stock after purchasing an additional 18,520 shares during the quarter. Forsta AP Fonden’s holdings in Alnylam Pharmaceuticals were worth $18,459,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Mediolanum International Funds Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $11,389,000. iA Global Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after acquiring an additional 16,133 shares in the last quarter. Perpetual Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $2,004,000. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after acquiring an additional 268,313 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 3rd quarter. Envestnet Asset Management Inc. now owns 118,964 shares of the biopharmaceutical company’s stock worth $54,248,000 after acquiring an additional 23,168 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $301.98 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $284.28 and a twelve month high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The stock has a market capitalization of $40.32 billion, a PE ratio of 82.51 and a beta of 0.31. The stock has a 50-day simple moving average of $309.38 and a 200 day simple moving average of $354.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the firm earned ($0.44) EPS. The firm’s revenue was up 96.4% compared to the same quarter last year. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on ALNY. Citigroup began coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They set a “buy” rating and a $380.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 5th. Chardan Capital reiterated a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This represents a 19.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the transaction, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This trade represents a 6.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,255 shares of company stock worth $6,930,337 in the last ninety days. 0.86% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.